Showing 8131-8140 of 20875 results for "".
Home Monitoring of Blood Sugar Did Not Improve Glycemic Control After 1 Year
https://reachmd.com/programs/the-jama-report/home-monitoring-blood-sugar-did-not-improve-glycemic-control-after-1-year/9653/A study in JAMA suggests that self-monitoring should not be routine in patients with type 2 diabetes who are not treated with insulinUnfair Treatment of Phase I Clinical Trial Subjects
https://reachmd.com/programs/clinicians-roundtable/unfair-treatment-of-phase-i-clinical-trial-subjects/3395/Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University, discusses with host Dr. Maurice Pickard what appears to be a ‘job' that may exploit the underclass in Phase 1 clinical studies. The poor in the studies are less likely to have access to the drugs when aKey Insights from GRADE: Exploring Data on Glycemia Reduction in T2D
https://reachmd.com/programs/diabetes-discourse/key-insights-from-grade-exploring-data-on-glycemia-reduction-in-t2d/14619/What did we learn about treatment options for patients with type 2 diabetes from the GRADE study?AACE Guidance in Action: When to Suspect and Treat Hypercortisolism in Adults with Diabetes
https://reachmd.com/programs/cme/aace-guidance-hypercortisolism-adults-diabetes/50073/Updated diabetes guidelines now recognize a new “other” category of diabetes linked to excess cortisol. This classification reflects emerging prevalence data showing that hypercortisolism may play a much larger role in diabetes development than previously understood. Let’s explore what these new guiDiabetes Research Suggests Better Long Term Outcomes with Early Insulin
https://reachmd.com/programs/everyday-family-medicine/diabetes-research-suggests-better-long-term-outcomes-with-early-insulin/7754/Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot studHow Overnight Glucose Levels Impact Daily Activities in T1D Patients
https://reachmd.com/programs/diabetes-discourse/how-overnight-glucose-levels-impact-daily-activities-in-t1d-patients/16255/Dive into the findings from a recent study that explored the impacts of overnight glucose levels on patients with type 1 diabetes.Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
https://reachmd.com/clinical-practice/cardiology/sotagliflozin-in-hfpef-without-diabetes-inside-the-sota-p-cardia-trial-from-aha-2025/39898/SOTA-P-CARDIA shows sotagliflozin improves LV mass, exercise capacity, and quality of life in non-diabetic HFpEF, supporting dual SGLT1/2 inhibition.Optimizing Outcomes in Diabetic Limb Preservation
https://reachmd.com/programs/clinicians-roundtable/optimizing-outcomes-in-diabetic-limb-preservation/36427/Effective diabetic limb preservation is not only about preserving length. It's equally important to focus on functional outcomes, taking a patient-centered approach that considers key factors like mobility, age, dialysis status, and blood flow. Join Dr. Paul Kim as he discusses these decision-makingA Look at LAI Antipsychotics for Bipolar I Disorder: A Preview of the Psych Congress
https://reachmd.com/programs/psych-congress-action-center/a-look-at-lai-antipsychotics-for-bipolar-i-disorder-a-preview-of-the-psych-congress/14192/Explore the benefits of long-acting injectable antipsychotics for bipolar disorder at this year’s Psych Congress.Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
https://reachmd.com/clinical-practice/nephrology/finerenone-efficacy-and-safety-in-patients-with-ckd-regardless-of-diabetes-status-insights-from-the-infinity-dataset/57917/Explore efficacy and safety findings for finerenone in CKD across diabetes status using data from the INFINITY dataset that were presented at ERA 2026.